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Chronic kidney disease is often characterized by enhanced
activity of the renin–angiotensin system (RAS) and the
sympathetic nervous system. Independent of their effect
on blood pressure, these systems also contribute to the
pathogenesis of both structural and functional cardiovascular
abnormalities and contribute importantly to clinical outcome.
There is much evidence that the diseased kidneys are of
central importance in the pathogenesis of both
abnormalities. Inhibitors of the RAS also reduce sympathetic
overactivity. Future research should be aimed at addressing
the pathophysiological mechanisms causing the enhanced
activities. Given the fact that even a small kidney lesion can
cause enhanced activity of the RAS and the sympathetic
nervous system, it is likely that these pathophysiological
mechanisms are operational in more disease conditions,
including essential hypertension, heart failure, and obesity/
metabolic syndrome.
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Both the renin–angiotensin system (RAS) and the sympa-
thetic nervous system are often activated in chronic kidney
disease (CKD). Independent of their effect on blood pres-
sure, these systems also contribute to the pathophysiology of
both structural and functional cardiovascular (CV) abnorm-
alities and contribute significantly to clinical outcome. There
is conclusive evidence that these systems do not operate
independently, but interact throughout the CV system.
In multiple species, including humans, kidney ischemia
leads to renin secretion. Inappropriate renin secretion in
relation to the state of sodium-volume balance has long been
recognized. Kidney ischemia is the central mechanism of
stimulation of the RAS and leads to high sympathetic nerve
activity (review by Siddiqi et al.1). In humans, intravenous
infusion of angiotensin II (AngII) stimulates muscle sympa-
thetic nerve activity (MSNA), which is the centrally originated
sympathetic outflow toward resistance vasculature. Even a
small locus of injury in one kidney, caused by intrarenal
injection of phenol, which does not affect glomerular filtration
rate, leads to hypertension in association with increased central
sympathetic activity.2 Renal denervation or unilateral ne-
phrectomy results in a reduction or total prevention of
hypertension.2 Long-term low-dose AngII infusion in rats
produces a gradual increase in blood pressure, which was
partially prevented by kidney denervation. Using the kidney
transplantation model, very convincing evidence is presented
that kidney AngII receptors are of crucial importance in the
pathogenesis of AngII-mediated hypertension and organ
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damage. Experimental studies suggest that AngII can act on
different sites, that is, in the kidney, in the central nervous
system, and on peripheral sites, enhancing noradrenaline
release from sympathetic nerve terminals. Whether the effects
of kidney injury on sympathetic nerve activity at the kidney
level are direct or mediated by AngII is unclear. Further,
increased sympathetic activity enhances the renin system.
Therefore, there may be a reciprocal potentiation. Thus,
kidney injury, which is generally characterized by an increased
activity of the RAS, can lead to high sympathetic nerve activity,
hypertension, and organ damage. Renal innervation has a
crucial role, because all these abnormalities are largely
prevented by destruction of the renal nerves, at least in
experimental settings (review by Siddiqi et al.1).
CLINICAL EVIDENCE OF SYMPATHETIC HYPERACTIVITY
IN CKD
In CKD patients, there is the parallel activation of the renin
and the sympathetic system.1 Further, in normal subjects and
in CKD patients, both systems show parallel shifts, with
changes in fluid status.3 These findings are very compatible
with the idea of a cause and effect relationship or a common
origin. Bilateral nephrectomy in CKD patients results in
MSNA levels comparable to normal, whereas unilateral
nephrectomy in healthy persons for transplantation purposes
does not result in change in MSNA.3 In CKD patients not on
dialysis, with a creatinine clearance ranging from 10 to
100 ml/min, and in healthy controls, sympathetic activity
increases with age, both in controls and in patients; however,
for any age, sympathetic activity in patients is higher than in
controls. In hemodialysis patients, MSNA is even higher.4
In sum, there seem to be (at least) two types of sympa-
thetic activity: a kind of ‘baseline activity’, present in healthy
controls, which exits also in bilaterally nephrectomized
patients when variables of the RAS are undetectable, and an
additional type, which is generated in diseased kidneys. This
last type closely correlates with the activation of the RAS. The
pathophysiological mechanisms are discussed in more detail
elsewhere.5,6
CLINICAL RELEVANCE
There is vast experimental evidence linking sympathetic
activity to CV organ damage. In humans as well, there is
direct evidence to suggest that this is the case. For instance,
sympathetic activity correlated with blood pressure.1 Much
more importantly, it has been shown that sympathetic
activity is associated with CV organ damage and outcome.
There are a number of studies showing the relationship
between sympathetic activity and left ventricular mass
(review by Siddiqi et al.1 and Mancia et al.7). Such a
relationship is also established in CKD patients.8 More
recently, it was reported in CKD patients not on dialysis that
left ventricular mass (quantified by magnetic resonance
imaging) is greater than in controls.9 Importantly, sympa-
thetic activity quantified by MSNA correlated closely with left
ventricular mass, despite the fact that blood pressure was
reasonably well controlled and all patients were on a RAS
inhibitor. In fact, MSNA appears to be a predictor for left
ventricular mass independently of blood pressure and other
relevant factors. In hemodialysis patients, the relationship
between plasma noradrenaline and all-cause mortality
and CV morbidity and mortality was established a few years
ago.10 Recently, this relationship was also reported in
predialysis patients.11 Several data sets suggest that sympa-
thetic activity is also involved in kidney failure progression
(review by Joles and Koomans6). Thus, to summarize, there is
substantial evidence that sympathetic activity contributes at
several levels to the development of CV organ damage.
TREATMENT
With these pathophysiological mechanisms in mind, it seems
logical to hypothesize that angiotensin-converting enzyme
inhibition reduces this sympathetic hyperactivity. Indeed,
more than a decade ago it was shown that enalapril reduced
MSNA in CKD patients.12 Importantly, use of amlodipine,
although an effective antihypertensive, resulted in an increase
in MSNA.12 The study showed that, by inhibiting RAS,
sympathetic activity was reduced. Over the past few years, in
a set of studies in CKD patients, the effect of different agents
was evaluated, including enalapril, losartan, eprosartan, and
aliskiren. The effects of the tested agents in the dosage used in
these studies did not differ much. During these treatments,
MSNA is reduced but not fully normalized.4,9,12–14 These
results indicate that additional treatment might be beneficial.
Moxonidine, which is a centrally acting sympatholytic agent,
added to the chronic treatment with eprosartan, resulted in a
further decrease in blood pressure and MNSA.13 This was
confirmed in dialysis patients in a recent study.15
The fact that additional sympathetic blockade indeed
improves prognosis was shown a few years ago. In dialysis
patients with impaired cardiac function treated with usual
medication including RAS inhibitor, addition of carvedilol
improved clinical outcome.16 Therefore, these data suggest
that we have a strong rationale to block sympathetic activity
and that addition of a sympatholytic agent to RAS inhibitor
treatment might be beneficial in selected patient groups.
More frequent dialysis is associated with better blood
pressure control. A switch from 3 times weekly hemodialysis
to 6 times weekly hemodialysis is associated with a decrease
in sympathetic activity, no change in cardiac output, and
therefore a decrease in peripheral vascular resistance.17 It is
tempting to speculate about the mechanisms of these effects;
apparently, the balance between sympatho-inhibiting and
stimulating factors changed substantially.
FUTURE PERSPECTIVES
An almost unexplored idea is that there is not only an enhanced
sympathetic activity but also an insufficient activity of the
‘counter balance’ system, that is, the parasympathetic system.
Unfortunately, this concept is difficult to study in humans.
If we accept the basic idea on the pathogenesis, that is, that
the diseased kidneys are the primary source of stimulation of
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the central nervous system to increase sympathetic outflow,
treatment can be delivered at several levels, that is, within
the kidneys, within the central nervous system, and at a
peripheral level.
Recently, catheter-based renal denervation was presented
as a treatment option. Renal nerves are located around the
arteries. These are both the afferent and efferent nerves. The
catheter is advanced from the femoral artery, a procedure
very similar to an ordinary arteriogram. By applications of
energy on various spots that in totality cover the circumfer-
ence, renal nerves can be destroyed. Initial results in a group
ofB50 patients with uncontrolled hypertension despite three
antihypertensive agents suggest a considerable and prolonged
effect. A substantial drop in MSNA was reported in one
patient.18 More recently, this antihypertensive effect was
confirmed in a randomized trial.19 These data give strong
support for the idea that, in humans as well, the kidneys are
important in the pathogenesis of hypertension, at least in this
category of patients. Interestingly, the effect after 12 months
seems even larger than that after 3 months. This treatment is
definitely worth studying in more detail and in a wider range
of patients for several reasons. First, it offers a new treatment
option with a prolonged effect of a single intervention.
Second, it will provide more information about pathophy-
siology. It is particularly interesting to identify those patients
in whom this very localized intervention has an effect on
systemic variables.20
In addition, it seems worth exploring options that address
kidney ischemia itself. There are some data to suggest that
manipulation of the hypoxia-inducible factor complex would
affect sympathetic activity and hypertension. Hypoxia-
inducible factor is the central complex trying to protect the
tissues and organs from the detrimental effects of hypoxia. It
forms the crucial step in the regulation of the expression of a
large number of genes, including, for instance, the EPO gene.
Expression of this complex can be manipulated by various
compounds, including the so-called prolyl hydroxylase inhibi-
tors. These compounds are now being tested as a sort of new
erythropoietin-like molecules; some of them also appear to
lower blood pressure. Of obvious concern is the fact that these
compounds may have unwanted effects, such neo-angiogenesis.
At present, much interest is focused on the potential of
bone marrow-derived cells to ‘repair’ tissue injury. The idea
that such treatment would reduce kidney failure progression/
repair kidney tissue, lower sympathetic outflow and blood
pressure is appealing.
Recent insights into the regulation of the RAS and
sympathetic activity may offer new avenues for exploring
therapeutic approaches, such as modulation of renalase. Renalase
is a recently described catecholamine-metabolizing enzyme.
Plasma concentrations are markedly reduced in CKD patients.
As mentioned above, there exists some evidence that
additional sympatholytic therapy (added to RAS inhibition)
might be beneficial. Several experts in the field have
already suggested this option, but it still needs to be studied
in more detail.
It is likely that the degree of kidney ischemia may differ
between patients, between kidney diagnoses, and between
stages of CKD. For instance, it is possible that, in dialysis
patients, progressive scarring ultimately destroys the kidneys,
with disappearance of the areas of ischemia and reduction of
the activated renin and sympathetic system. It is important to
focus research on these areas. Sympathetic activity is difficult
to measure in humans. Measurement of indices of the RAS
might be easier to implement, although these measurements
need to be taken in a very standardized manner. Modern
radiological techniques may be helpful. For instance, the
blood oxygen level-dependent magnetic resonance imaging
technique may identify areas of ischemia in tissue. It seems
worthwhile to apply this technique in CKD.
Finally, it is important to realize that already a small kidney
lesion, not affecting kidney function, can activate these
pathophysiological mechanisms. It is very likely that they are
also operational in other disease conditions, including, for
instance, some forms of essential hypertension, heart failure,
sleep apnea syndrome, and obesity/metabolic syndrome.
CONCLUSION
It is clear that injured kidneys are at the core of the
pathogenesis of the enhanced activity of the RAS and the
sympathetic nervous system. This knowledge can help us
define research questions in an effort to improve the
treatment of our patients (Figure 1).
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Figure 1 | Subjects for future research.
Define patient characteristics that are especially predictive
for the presence of an activated renin/sympathetic system.
Study the effect of additional sympatholytic therapy, for instance,
beta-blockers added to renin–angiotensin system (RAS) inhibitors,
on meaningful clinical end points in chronic kidney disease (CKD)
patients over a wide range of CKD stages.
Study the effect on meaningful clinical end points of renal
denervation in properly designed clinical trials in a wider range of
patients.
Focus on therapies aiming to address the central abnormalities
in pathogenesis, namely, kidney injury/ischemia; for instance,
stem cell infusion, modulators of hypoxia-inducible factor (HIF),
and renalase.
Apply modern radiological techniques that may help to
identify/quantify/localize areas of kidney ischemia. Study whether
these techniques can be used not only as a diagnostic tool
but also to guide/monitor therapy.
Kidney International Supplements (2011) 1, 13–16 15
PJ Blankestijn et al.: The sympathetic system, RAS, and CKD min i rev iew
received funding from Amgen and Baxter. GL has received consulting
fees from Amgen and Sandoz. GL has also received lecture fees from
Amgen, Sandoz, Genzyme, and Shire. PJB has received consulting
fees from Medtronic and has received grant support from Ardian and
Novartis AG. RA has received consulting fees from Amgen, Abbott
Laboratories, Merck, Affymax, Takeda Pharmaceutical Company,
Daiichi Sankyo, Celgene, Watson Pharmaceuticals, and Rockwell
Medical. RA has also received lecture fees from Abbott Laboratories,
Merck, and Medscape. ZM has received lecture fees from Amgen,
Shire, Genzyme, FMC, and Merck Sharp & Dohme. ZM has received
grant support from Baxter, Amgen, FMC, Shire, and Genzyme. The
remaining authors declared no competing interests.
REFERENCES
1. Siddiqi L, Joles JA, Grassi G et al. Is kidney ischemia the central
mechanism in parallel activation of the renin and sympathetic system?
J Hypertens 2009; 27: 1341–1349.
2. Campese VM. Neurogenic factors and hypertension in renal disease.
Kidney Int Suppl 2000; 75: S2–S6.
3. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity is
inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003;
14: 3239–3244.
4. Neumann J, Ligtenberg G, Klein IH et al. Response to sympathetic
hyperactivity in hypertensive chronic kidney disease patients
is reduced during standard treatment. Hypertension 2007; 49:
506–510.
5. Neumann J, Ligtenberg G, Klein II et al. Sympathetic hyperactivity in
chronic kidney disease: pathogenesis, clinical relevance, and treatment.
Kidney Int 2004; 65: 1568–1576.
6. Joles JA, Koomans HA. Causes and consequences of increased
sympathetic activity in renal disease. Hypertension 2004; 43:
699–706.
7. Mancia G, Grassi G, Giannattasio C et al. Sympathetic activation in the
pathogenesis of hypertension and progression of organ damage.
Hypertension 1999; 34: 724–728.
8. Zoccali C, Mallamaci F, Tripepi G et al. Norepinephrine and concentric
hypertrophy in patients with end-stage renal disease. Hypertension 2002;
40: 41–46.
9. Siddiqi L, Prakken NH, Velthuis BK et al. Sympathetic activity in chronic
kidney disease patients is related to left ventricular mass despite
antihypertensive treatment. Nephrol Dial Transplant 2010; 25:
3272–3277.
10. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts
survival and incident cardiovascular events in patients with end-stage
renal disease. Circulation 2002; 105: 1354–1359.
11. Penne EL, Neumann J, Klein IH et al. Sympathetic hyperactivity and
clinical outcome in chronic kidney disease patients during standard
treatment. J Nephrol 2009; 22: 208–215.
12. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic
hyperactivity by enalapril in patients with chronic renal failure. N Engl J
Med 1999; 340: 1321–1328.
13. Neumann J, Ligtenberg G, Oey L et al. Moxonidine normalizes
sympathetic hyperactivity in patients with eprosartan-treated chronic
renal failure. J Am Soc Nephrol 2004; 15: 2902–2907.
14. Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce
sympathetic hyperactivity in patients with chronic renal failure.
J Am Soc Nephrol 2003; 14: 425–430.
15. Hausberg M, Tokmak F, Pavenstadt H et al. Effects of moxonidine on
sympathetic nerve activity in patients with end-stage renal disease.
J Hypertens 2010; 28: 1920–1927.
16. Cice G, Ferrara L, Di BA et al. Dilated cardiomyopathy in dialysis
patients–beneficial effects of carvedilol: a double-blind, placebo-
controlled trial. J Am Coll Cardiol 2001; 37: 407–411.
17. Zilch O, Vos PF, Oey PL et al. Sympathetic hyperactivity in haemodialysis
patients is reduced by short daily haemodialysis. J Hypertens 2007; 25:
1285–1289.
18. Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation
for uncontrolled hypertension. N Engl J Med 2009; 361: 932–934.
19. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation
in patients with treatment-resistant hypertension (The Symplicity HTN-2
Trial): a randomised controlled trial. Lancet 2010; 376: 1903–1909.
20. Blankestijn PJ, Ritz E. Renal denervation: potential impact on
hypertension in kidney disease? Nephrol Dial Transplant 2011 (in press).
16 Kidney International Supplements (2011) 1, 13–16
min i rev iew PJ Blankestijn et al.: The sympathetic system, RAS, and CKD
